Maravai LifeSciences (NASDAQ:MRVI) Sets New 52-Week Low – Should You Sell?

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)’s stock price hit a new 52-week low during mid-day trading on Wednesday . The company traded as low as $4.05 and last traded at $4.18, with a volume of 107889 shares trading hands. The stock had previously closed at $4.10.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on MRVI shares. The Goldman Sachs Group lowered Maravai LifeSciences from a “neutral” rating to a “sell” rating and decreased their target price for the company from $7.00 to $4.25 in a research report on Thursday, December 5th. Wolfe Research started coverage on Maravai LifeSciences in a research report on Thursday, November 14th. They issued a “peer perform” rating for the company. Royal Bank of Canada dropped their price target on Maravai LifeSciences from $17.00 to $13.00 and set an “outperform” rating on the stock in a research report on Friday, November 8th. William Blair reissued a “market perform” rating on shares of Maravai LifeSciences in a report on Friday, November 8th. Finally, Robert W. Baird lowered their price objective on Maravai LifeSciences from $10.00 to $9.00 and set an “outperform” rating on the stock in a research note on Friday, November 8th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Maravai LifeSciences has an average rating of “Hold” and a consensus target price of $10.28.

Maravai LifeSciences Stock Performance

The company has a current ratio of 10.74, a quick ratio of 9.94 and a debt-to-equity ratio of 0.89. The company has a market cap of $1.04 billion, a P/E ratio of -2.51 and a beta of -0.08. The company’s fifty day moving average is $5.09 and its 200 day moving average is $6.71.

Insider Activity

In related news, General Counsel Kurt Oreshack sold 25,000 shares of the stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $5.03, for a total transaction of $125,750.00. Following the completion of the sale, the general counsel now directly owns 167,618 shares in the company, valued at $843,118.54. This represents a 12.98 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 0.63% of the company’s stock.

Hedge Funds Weigh In On Maravai LifeSciences

Large investors have recently bought and sold shares of the stock. Performa Ltd US LLC grew its holdings in shares of Maravai LifeSciences by 614.3% in the fourth quarter. Performa Ltd US LLC now owns 5,000 shares of the company’s stock worth $27,000 after purchasing an additional 4,300 shares during the last quarter. FNY Investment Advisers LLC grew its holdings in Maravai LifeSciences by 600.0% in the 4th quarter. FNY Investment Advisers LLC now owns 7,000 shares of the company’s stock worth $38,000 after acquiring an additional 6,000 shares during the last quarter. Venturi Wealth Management LLC purchased a new position in shares of Maravai LifeSciences in the third quarter valued at about $47,000. Farther Finance Advisors LLC raised its stake in shares of Maravai LifeSciences by 3,541.4% during the fourth quarter. Farther Finance Advisors LLC now owns 10,196 shares of the company’s stock valued at $56,000 after acquiring an additional 9,916 shares during the last quarter. Finally, Cibc World Markets Corp bought a new position in shares of Maravai LifeSciences during the fourth quarter valued at about $56,000. 50.25% of the stock is owned by hedge funds and other institutional investors.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.